Moving to expand the evidence base for the future of structural heart disease therapy, Medtronic, Inc. (NYSE: MDT), announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system, a minimally-invasive alternative to open-heart surgery for aortic valve replacement. The CoreValve Advance clinical study began enrolling patients last week, with the first two implants occurring in Germany...